The in vitro effect of pidotimod on some immune functions in cancer patients

Immunopharmacology and Immunotoxicology

Volumn 19, Issue 1, 1997, Pages 37-51

  Di Renzo, M ^a   Pasqui, A L ^a   Bruni, F ^a   Saletti, M ^a   Bova, G ^a   Chiarion, C ^a   Girardello, R ^b   Ferri, P ^b   Auteri, A ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Poli Industria Chimica SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CONCANAVALIN A; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; PIDOTIMOD;

ARTICLE; BIOASSAY; BLOOD; CANCER PATIENT; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0031054501     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979709038532     Document Type: Article

References (33)

1. Monson, J. R., Ramsden, C. W., Guillon, P. J. Decreased interleukin-2 production in patients with gastrointestinal cancer, Br. J. Surg., 73:483, 1987.
2. Monson, J. R., Ramsden, C. W., Giles, G. R., Brennan, T. G., Guillon, P. J. Lymphokine-activated killer cells in patients with gastrointestinal cancer, Gut, 28:1420, 1987.
3. Anastasopoulos, E., Reclos, G. J., Baxevanis, C. N., Gritzapis, A. D., Tsilivakos, V., Panagiotopoulos, N., Fotiou, S., Missitzis, I., Karydas I., Papamichail, M. Monocyte disorders associated with T cell defects in patients with solid tumors, Anticancer Res., 12:489, 1992.
4. Rao, B., Wanebo, H. J., Pinsky, C. M., Stearns, M., Oettgen, H. Delayed hypersensivity reactions in patients with carcinoma ot the colon and rectum, Surg. Gynecol. Obset.,144:677, 1977.
5. Wanebo, H. J., Pinsky, C. M., Beattie, E. J., Oettgen, H. F. Immunocompetence testing in patients with one of the four common operable cancers. A review, Clin. Bull., 8:15, 1978.
6. Zembala, M., Mytar, B., Popiela, T., Asherson, G. L. Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells, Int. J. Cancer, 19:605, 1977.
7. Figarella, E. F., Morillo, F., Blanca, I., Bianco, C. Failure of cell-mediated effector mechanisms in lung cancer, J. Natl. Cancer Inst., 73:1, 1984.
8. North, R. J. Down-regulation of the antitumor immune responses, Adv. Cancer Res., 45:1, 1986.
9. Funa, K., Nillson, B., Jacobson, G., Alm, G. V. Decreased natural killer cell activity and interferon production by leukocytes in patients with adenocarcinoma of the pancreas, Br. J. Cancer, 50:231, 1984.
10. Pugliese, A., Girardello, R., Marinelli, L., Forno, B., Pattarino, P. L., Biglino, A. Evaluation of Pidotimod effects on some immune parameters, J. Chemother., 3:144, 1991.
11. Meroni, P. L., Capsoni, F., Barcellini, W., Minonzio, F., Borghi, M. O., Ongari, A. M., Girardello, R., Zanussi, C. In vitro and ex vivo effects of PGT/1A on human polymorphonuclear leukocytes, Pharmacol. Res., 22:328, 1990.
12. Illeni, M. T., Bombelli, G., Mailland, F., Pattarino, P. L. Effect of PGT/1A on blastogenesis with mitogens: an ex vivo study, J. Chemother., 3:153, 1991.
13. Illeni, M. T., Bombelli, G., Pattarino, P. L., Poli, A. NK cell cytotoxic activity induced by a synthetic immunostimulant (Pidotimod): an in vitro study, J. Chemother., 3:156, 1991.
14. Auteri, A., Pasqui, A. L., Bruni, F., Saletti, M., Di Renzo, M., Bova, G. Effect of Pidotimod, a new immunostimulating agent, on some aspects of immune response, In vitro study. Pharmacol. Res., 26:196, 1992.
15. Auteri, A., Pasqui, A. L., Gotti, G., Bruni, F., Saletti, M., Di Renzo, M., Bova, G., Borlini, G., Gori, S., Fanetti, G., Campoccia, G., Maggiore, D., Girardello, R. The effect of a new biological response modifier (Pidotimod) on surgery-associated immunodeficiency, Int. J. Immunotherapy, IX(2),95, 1993.
16. Steinhauser, E. H., Doyle, A. T., Reed, J., Kadish, A. S. Defective natural cytotoxicity in patients with cancer: normal numbers of effector cells but decreased recycling capacity in patients with advanced disease, J. Immunol., 129:2255, 1982.
17. Balch, C. M., Tilden, A. B., Dougherty, P. A., Clou, G., Abu, T. Depressed levels of granular lymphocytes with natural killer cell function in 247 patients, Ann. Surg., 198:192, 1983.
18. Whittaker, M. G., Rees, K., Clark, C. C. Reduced lymphocyte transformation in breast cancer, Lancet, i:892, 1971.
19. Kosmidis, P. A., Baxevanis, C. N., Tsavaris, N. et al. The prognosis significance of immune parameters in patients with renal cancer treated with interferon-A2b, J. Clin. Oncol., 10:1153, 1992.
20. Fortner, J. G., Kim, D. K., Hopkins, L. Immunologic function in patients with carcinoma of the pancreas, Surg. Gynecol. Obstet., 150:215, 1980.
21. Nakayama, E., Asamo, S., Takuwa, N. et al. Decreased TCGF activity in the culture medium of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer, Clin. Exp. Immunol., 51:511, 1983.
22. Baxevanis, C. N., Reclos, G. J., Gritzapis, A. D. et al. Comparison of immune parameters in patients with one or two primary malignant neoplasms, Nat. Immun., 12:41, 1993.
23. Finke, J. H., Zea, A. H., Stanley, J. et al. Loss of T-cell receptor chain and p561ck in T-cells infiltrating human renal cell carcinoma, Cancer Res., 53:5613, 1993.
24. Nakagomi, H., Peterson, M., Magnusson, I. et al. Decreased expression of the signal-transducing chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma, Cancer Res., 53:5610, 1993.
25. Farace, F., Angevin, E., Vanderplancke, J., Escudier, B., Triebel F. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL2 administration, Int. J. Cancer, 59:752, 1994.
26. Torbett B. E., Skidmore, B., Clark, W. R. Multiple pathways for antigen-independent activation of a T helper hybridoma, Eur. J. Immunol., 16:933, 1986.
27. Rey, A., Klein, B., Rucheton, M., Carraux, J., Zagury, D., Thierry, C., Serrou, B. Human autologous rosettes. IV. Their relation with IL-2 activity, production and natural killer cells in cancer patients, Cell. Immunol., 86:155, 1984.
28. Smith, K. A. Interleukin 2: inception, impact and implications, Science, 240:1169, 1988.
29. Siegel, J. P., Sharon, M., Smith, P. L., Leonard, W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferating activities, Science, 238:75, 1987.
30. Itoh K, Tilden AB, Kumagai K, Balch CM. Leu-11+ lymphocytes with natural killer activity are precursors of recombinant interleukin-2-induced activated killer cells. J. Immunol., 134:802, 1985.
31. Pross, H. F. The involvement of natural killer cells in human malignant disease, in Immunology of natural killer cells, edited by E. Lotzova and R. B. Herbermann, p. 11, Boca Raton, CRC Press, 1987.
32. Clerici, M., Stocks, N. I., Zajac, R. A. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals, Nature, 339:383, 1989.
33. Mizoguchi, H., O'Shea, J. J., Longo, C. M. et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice, Science, 258:1795, 1992.